| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.57 | 12.18 | 54.41 | 5.97 |
Op profit growth | 19.2 | 3.1 | 93.35 | -15.35 |
EBIT growth | 14.8 | -1.65 | 80.53 | -21.86 |
Net profit growth | -12.43 | -1.02 | 100.91 | -39.16 |
Profitability ratios (%) | ||||
OPM | 24.07 | 23.13 | 25.17 | 20.1 |
EBIT margin | 16.72 | 16.69 | 19.03 | 16.28 |
Net profit margin | 7.92 | 10.36 | 11.75 | 9.03 |
RoCE | 9.58 | 10.3 | 13.36 | 8.59 |
RoNW | 2.01 | 2.58 | 3.14 | 1.85 |
RoA | 1.13 | 1.59 | 2.06 | 1.19 |
Per share ratios (₹) | ||||
EPS | 6.43 | 7.05 | 7.26 | 7.55 |
Dividend per share | 0.5 | 0 | 0 | 1 |
Cash EPS | -1.38 | 0.21 | 1.63 | -0.21 |
Book value per share | 70.23 | 63.55 | 55.88 | 86.34 |
Valuation ratios | ||||
P/E | 52.02 | 57.98 | 37.27 | 39.35 |
P/CEPS | -242.25 | 1,931.33 | 165.67 | -1,403.62 |
P/B | 4.76 | 6.43 | 4.84 | 3.44 |
EV/EBIDTA | 19.95 | 27.01 | 19.37 | 34.63 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 16.11 |
Tax payout | -16.25 | -19.52 | -27.46 | -25.72 |
Liquidity ratios | ||||
Debtor days | 79.42 | 69.67 | 65.56 | 86.17 |
Inventory days | 92.87 | 84.37 | 61.86 | 60.09 |
Creditor days | -112.21 | -121.03 | -113.98 | -119.99 |
Leverage ratios | ||||
Interest coverage | -20.24 | -20.66 | -18.67 | -10.91 |
Net debt / equity | 0.4 | 0.32 | 0.25 | 0.18 |
Net debt / op. profit | 1.72 | 1.49 | 1.07 | 1.13 |
Cost breakup (₹) | ||||
Material costs | -33.21 | -31.41 | -32.23 | -39.67 |
Employee costs | -22.97 | -24.37 | -22.91 | -22.58 |
Other costs | -19.73 | -21.07 | -19.68 | -17.63 |
Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Just Dial, PCBL, etc.
The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously
Here are some of the stocks that may see significant price movement today: Varun Beverages, NHPC, Hindustan Zinc, etc.
The USFDA released an Establishment Inspection Report with a "Voluntary Action Indicated" status for Biocon's Active Pharmaceutical Ingredients facility in Bengaluru.
Here are some of the stocks that may see significant price movement today: Reliance Industries, Biocon, Bharat Forge, etc.
Here are some of the stocks that may see significant price movement: Godrej Consumer Products, Biocon, Paytm, etc.
YESINTEK targets specific proteins that trigger inflammation, which presents new therapeutic options in the chronic management of autoimmune diseases.
Ethiopia, with a prevalence of 2-3%, is one of the top four nations in Sub-Saharan Africa for adult diabetics.
The combined cGMP inspection and pre-licensing inspection (PLI), which took place between July 15 and July 26, 2024, is the subject of this update.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
